The APPROACH trial was a randomized double-blinded placebo-controlled trial that enrolled 66 patients with familial chylomicronemia syndrome (FCS), a rare genetic disease caused by an inactivating mutation of both alleles of LPL genes and genes encoding other proteins required for LPL activity [91]. Here, LPL is linked to hereditary disease.